IP Library Granted Patent US 8,097,722
Granted Patent B2
US 8,097,722 · App. 12/418,946 · Granted Jan 17, 2012

Inhibitors of polyisoprenylated methylated protein methyl esterase

Assignee: Florida Agricultural and Mechanical University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,722
App. No.
12/418,946
Granted
Jan 17, 2012
Kind
B2
Abstract

Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R 1 -X-A-B(R 2 )-Y or R 1 -X-A(R 2 )-B-Y, where R 1 is preferably a polyisoprenyl group, X is a linking group, Y is a group that promotes affinity interactions to the active site of PMPMEase and imparts hydrolysis resistance to the inhibitor, A and B are bridge atoms, and R 2 is a characteristic-providing substituent.

Claims (14)

1. An inhibitor of the enzyme prenylated methylated protein methyl esterase (PMPMEase), which has the formula

where R 1 is a group selected from substituted or unsubstituted prenyl or polyisoprenyl;

X is a linking group;

the two atoms between the X and Y groups are the bridge and are selected from C, N, O, and S;

R 2 is a group selected to impart increased aqueous solubility or potency, and includes an open chain alkyl, alicyclic, aryl, or aryloxy group containing one or more salt-forming basic or acidic groups separated from the bridge by a tether; and

Y is selected from

where R 3 is alkyl, substituted alkyl, aryl, substituted aryl, SR 5 , OR 5 (except carboxyl esters), NHR 5 or NR 5 R 6 , R 4 is alkyl, substituted alkyl, aryl or substituted aryl and R 5 and R 6 are alkyl, substituted alkyl, aryl or substituted aryl; and

wherein if Y is

and the bridge atoms are both C then R 3 is not OR 5 .

2. The inhibitor of claim 1 , wherein R 1 is a substituted or unsubstituted trans,trans-farnesyl or an all trans-geranylgeranyl group.

3. The inhibitor of claim 1 , wherein X is S, Se, SO, SO 2 , O, NH, NR, or CH 2 .

4. The inhibitor of claim 1 , wherein R 2 substitutes the polypeptide portion of an endogenous protein substrate.

5. The inhibitor of claim 1 , wherein the salt forming basic or acidic group is selected from the group consisting of amino, carboxylic acid, sulfonic, and phosphoric.

6. The inhibitor of claim 1 , wherein Y imparts selectivity between PMPMEase isoforms.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 20, 2015
From: FLORIDA AGRICULTURAL AND MECHANICAL UNIV
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035740/0667 →
Continuity (2)
Continuation In Part 12098712 · Apr 7, 2008
Related Publication 20100087526A1 · Apr 8, 2010